Provided by Tiger Fintech (Singapore) Pte. Ltd.

Inhibrx Biosciences

57.29
+28.93102.01%
Post-market: 56.10-1.1900-2.08%19:59 EDT
Volume:6.08M
Turnover:317.31M
Market Cap:829.87M
PE:-5.41
High:60.20
Open:49.13
Low:46.01
Close:28.36
52wk High:60.20
52wk Low:10.81
Shares:14.49M
Float Shares:7.81M
Volume Ratio:13.18
T/O Rate:77.86%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-10.5804
EPS(LYR):114.01
ROE:-113.71%
ROA:-26.29%
PB:12.10
PE(LYR):0.50

Loading ...

Nasdaq Net Change Percentage Gainers & Losers

Dow Jones
·
Yesterday

Top Midday Gainers

MT Newswires Live
·
Yesterday

Stocks Soar To Records After Weak Inflation, Ford Jumps 10%: What's Moving Markets Friday?

Benzinga_recent_news
·
Yesterday

Ford, Inhibrx Biosciences, Comfort Systems, Western Union And Other Big Stocks Moving Higher On Friday

Benzinga
·
Oct 24

Why Are Inhibrx Biosciences Shares Soaring 76% After Hours?

Benzinga
·
Oct 24

BRIEF-Inhibrx Biosciences Reports Positive Topline Results From Its Registrational Trial Of Ozekibart (Inbrx-109) In Chondrosarcoma And Provides Updates On Colorectal Cancer And Ewing Sarcoma Expansion Cohorts

Reuters
·
Oct 24

Inhibrx shares surge after bone cancer drug slows disease progression in trial

Reuters
·
Oct 24

Inhibrx Biosciences Shares up 72.88% at $49.03 in Extended Trade After Registrational Trial Results for Ozekibart

THOMSON REUTERS
·
Oct 24

Inhibrx reports positive topline results from registrational trial of ozekibart

TIPRANKS
·
Oct 24

Inhibrx Biosciences Inc - Plans to File Bla in Q2 2026

THOMSON REUTERS
·
Oct 24

Inhibrx Biosciences Inc - Ozekibart Meets Primary Endpoint in Chondrosarcoma

THOMSON REUTERS
·
Oct 24

Inhibrx Biosciences Reports Positive Topline Results From Its Registrational Trial of Ozekibart (Inbrx-109) in Chondrosarcoma and Provides Updates on Colorectal Cancer and Ewing Sarcoma Expansion Cohorts

THOMSON REUTERS
·
Oct 24

Inhibrx Biosciences Inc - Ozekibart Reduces Risk of Disease Progression by 52%

THOMSON REUTERS
·
Oct 24

Inhibrx Biosciences Inc - 23% Response Rate and 92% Disease Control Rate

THOMSON REUTERS
·
Oct 24

BRIEF-Inhibrx To Host Webcast Presentation Of Topline Results From Its Registrational Trial Of Ozekibart (Inbrx-109) In Chondrosarcoma And To Provide Updates On Colorectal Cancer And Ewing Sarcoma Expansion Cohorts

Reuters
·
Oct 23

Inhibrx Biosciences Announces Topline Results from Ozekibart Chondrosarcoma Trial

Reuters
·
Oct 23

Inhibrx to Host Webcast Presentation of Topline Results From Its Registrational Trial of Ozekibart (Inbrx-109) in Chondrosarcoma and to Provide Updates on Colorectal Cancer and Ewing Sarcoma Expansion Cohorts

THOMSON REUTERS
·
Oct 23

Major Stakeholder Sells Massive Inhibrx Stock!

TIPRANKS
·
Oct 10

Viking Global Investors LP Reports Disposal of Common Shares in Inhibrx Biosciences Inc

Reuters
·
Oct 10

Inhibrx Biosciences Q2 EPS $(1.85) Beats $(2.76) Estimate, Sales $1.300M Up From $100.000K YoY

Benzinga
·
Aug 14